ARRY biopharma is up over 50% this year so far, as acquisition of LOXO, whose most significant clinical assets were licensed from ARRY, sparks rumors of a possible ARRY acquisition. Plus ARRY presented updated data for its lead drug candidates in colorectal cancer, continuing to show best in class results for colorectal cancer patients with the BRAF mutations. Finally, the company recently announced excellent 61% quarter over quarter revenue growth for its lead assets, which launched in the middle of 2018. At these levels we will likely keep ARRY at a low level in the fund, or take all profits.
top of page
bottom of page